XML 17 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Redeemable Convertible Noncontrolling Interests and Stockholders' Deficit (Unaudited) - USD ($)
$ in Thousands
Total
Equity Compensation Plans
Employee Stock Purchase Plan
Satisfy Tax Withholding
Redeemable Convertible Noncontrolling Interests
Common Stock
Common Stock
Equity Compensation Plans
Common Stock
Employee Stock Purchase Plan
Common Stock
Satisfy Tax Withholding
Treasury Stock
Additional Paid-in Capital
Additional Paid-in Capital
Equity Compensation Plans
Additional Paid-in Capital
Employee Stock Purchase Plan
Additional Paid-in Capital
Satisfy Tax Withholding
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Parent
Parent
Equity Compensation Plans
Parent
Employee Stock Purchase Plan
Parent
Satisfy Tax Withholding
Non-controlling Interests
Beginning balance at Dec. 31, 2021 [1] $ (867,002)         $ 154       $ (275,000) $ 841,530       $ (132) $ (1,436,966) $ (870,414)       $ 3,412
Temporary equity, beginning balance at Dec. 31, 2021 [1]         $ 1,423                                
Beginning balance, shares at Dec. 31, 2021 [1]           147,343,323       6,191,761                      
Issuance of shares   $ 104 $ 966                 $ 104 $ 966         $ 104 $ 966    
Issuance of shares, shares             229,926 127,635                          
Repurchase of shares to satisfy tax withholding       $ (110)                   $ (110)           $ (110)  
Repurchase of shares to satisfy tax withholding, shares                 (12,491)                        
Stock-based compensation 25,423                   25,423           25,423        
Issuance of noncontrolling interests 89                                       89
Transfers from (to) noncontrolling interests 48                   (317)           (317)       365
Temporary Equity, transfers from (to) noncontrolling interest         (47)                                
Unrealized gain (losses) on available-for-sale securities (251)                           (251)   (251)        
Net loss (200,290)                             (196,397) (196,397)       (3,893)
Temporary Equity, net loss         (1,040)                                
Ending balance at Mar. 31, 2022 (1,041,023)         $ 154       $ (275,000) 867,596       (383) (1,633,363) (1,040,996)       (27)
Temporary equity, ending balance at Mar. 31, 2022         336                                
Ending balance, shares at Mar. 31, 2022           147,688,393       6,191,761                      
Beginning balance at Dec. 31, 2022 [1] (1,243,335) [2]         $ 157       $ (275,000) 938,703       (328) (1,918,149) (1,254,617)       11,282
Temporary equity, beginning balance at Dec. 31, 2022 (1,589)       (1,589) [1]                                
Beginning balance, shares at Dec. 31, 2022 [1]           150,625,572       6,191,761                      
Issuance of shares   $ 193 $ 1,809       $ 1         $ 192 $ 1,809         $ 193 $ 1,809    
Issuance of shares, shares             834,427 192,200                          
Repurchase of shares to satisfy tax withholding       $ (512)                   $ (512)           $ (512)  
Repurchase of shares to satisfy tax withholding, shares                 (40,491)                        
Stock-based compensation 24,330                   24,330           24,330        
Issuance of common stock under Follow-on offering 143,016         $ 9         143,007           143,016        
Issuance of common stock under Follow-on offering, shares           8,823,530                              
Issuance of noncontrolling interests 42                                       42
Transfers from (to) noncontrolling interests (1,633)                   (2,843)           (2,843)       1,210
Temporary Equity, transfers from (to) noncontrolling interest         1,633                                
Deconsolidation of PellePharm 3,950                   1,949         850 2,799       1,151
Temporary Equity, deconsolidation of PellePharm         899                                
Unrealized gain (losses) on available-for-sale securities 316                           316   316        
Net loss (141,585)                             (140,156) (140,156)       (1,429)
Temporary Equity, net loss         (1,147)                                
Ending balance at Mar. 31, 2023 (1,213,409)         $ 167       $ (275,000) $ 1,106,635       $ (12) $ (2,057,455) $ (1,225,665)       $ 12,256
Temporary equity, ending balance at Mar. 31, 2023 $ (204)       $ (204)                                
Ending balance, shares at Mar. 31, 2023           160,435,238       6,191,761                      
[1] The consolidated balances as of December 31, 2022 and 2021 are derived from the audited consolidated financial statements as of those dates.
[2] The condensed consolidated balance sheet as of December 31, 2022 is derived from the audited consolidated financial statements as of that date.